September 19, 2011
Takeda Pharmaceutical announced on September 8 that it has initiated a domestic PIII clinical trial of the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes SYR-472. The company expects to file for approval in FY2013. SYR-472...read more